文献速递临床试验与 GCP流行病学与生物统计

药师主导的药物审查对儿童和老年人群再入院的影响:随机开放标签对照试验研究方案

Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial.
PubMed 文献 · Trials · 2017-02-09

本研究为随机开放标签对照试验,计划纳入1400例住院患者,随机分为药师主导药物审查组和常规护理组,主要终点为首次出院后30天再入院和/或死亡发生率。研究旨在评估药师主导药物审查对儿童和老年人群出院后再入院、死亡及治疗满意度的影响。

要点

  • 纳入1400例住院患者,随机分为药师主导药物审查组与常规护理组。
  • 主要终点为首次出院后30天再入院和/或死亡发生率。
  • 药师主导药物审查流程包括药物重整、治疗审查和药物联络服务。

核心结论

  • 研究旨在评估药师主导药物审查对儿童和老年人群出院后再入院和/或死亡发生率及患者治疗满意度的影响。

研究设计与样本

  • 随机开放标签对照试验,计划纳入1400例住院患者,随机分为药师主导药物审查组和常规护理组。
  • 药师主导药物审查流程包括药物重整、治疗审查和药物联络服务。

主要发现

  • 研究方案未报告结果数据;主要终点为首次出院后30天再入院和/或死亡发生率。
  • 次要终点包括首次出院后30天再入院率、急诊就诊率、死亡率、就诊次数和患者治疗满意度。

关键数值与推荐

  • 主要终点:首次出院后30天再入院和/或死亡发生率。
  • 次要终点:首次出院后30天再入院率、急诊就诊率、死亡率、就诊次数和患者治疗满意度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Early hospital readmission of patients after discharge is a public health problem. One major cause of hospital readmission is dysfunctions in integrated pathways between community and hospital care that can cause adverse drug events. Furthermore, the French ENEIS 2 study showed that 1.3% of hospital stays originated from serious adverse drug events in 2009. Pharmacy-led medication reviews at hospital transitions are an effective means of decreasing medication discrepancies when conducted at admission or discharge. However, it is difficult to assess the true impact of pharmacist-led medication reviews in specific high-risk populations, such as pediatric and geriatric populations. In such a context, it is important to demonstrate the effectiveness of medication reconciliation as part of a standardized medication review process-in pediatric and elderly populations-on all-cause readmissions in a large randomized controlled clinical trial. The aim of this study is to assess the impact of the pharmacist-led medication review on the rate of readmissions and/or death after hospital discharge and patient treatment satisfaction. METHODS/DESIGN: The study is a randomized controlled clinical trial. A total of 1400 hospitalized patients will be randomized in two groups: (1) the experimental group (group receiving a pharmacist-led medication review) and (2) the control group (group receiving usual care). The pharmacist-led medication review process includes medication reconciliation, treatment review and medication liaison service. The primary endpoint will be the rate of readmissions and/or death at 30 days following initial hospitalization discharge. The secondary endpoints will be the rate of hospital readmission, the rate of emergency department visits, the rate of mortality, the number of consultations and patient treatment satisfaction at 30 days following initial hospitalization discharge. DISCUSSION: A randomized controlled trial provides the most extensive evidence on the impact of pharmacist-led medication reviews on early hospital readmission for extreme age populations. TRIAL REGISTRATION: Current Controlled Trials, NCT02734017 . Registered on 4 May 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Renaudin P, Baumstarck K, Daumas A, et al. Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial. Trials. 2017. PMID: 28183322. doi:10.1186/s13063-017-1798-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。